Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Wednesday’s Unusual Options Activity Reveals 3 Standout Long Straddle Plays

There were 37 unusually active options in Wednesday Trading that expire in 30 days. This DTE reveals three standout long straddle plays that provide a nice combination of time and cost, while allowing increased volatility to take its course.

Ursula von der Leyen faces confidence vote in far-right challenge

Ursula von der Leyen faces confidence vote in far-right challenge

A range of accusations have been levelled against the European Commission president

The Independent UK

Von der Leyen survives censure vote but faces calls to reverse EU’s rightward drift

Von der Leyen survives censure vote but faces calls to reverse EU’s rightward drift

Debate on motion against European Commission president lifts lid on simmering discontent among MEPs

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer Earnings Preview: What to Expect

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company’s bottom-line figure.

Top 5 Undervalued Dividend Stocks With Strong Payout Potential

Seemingly undervalued dividend stocks, such as BAC, F, MO, VZ, and PFE, offer a rare combination of strong yields and attractive valuations.

Regulator warns of small risk of serious condition in people having RSV jab

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

Evening Standard

Turbulent research landscape imperils US brain gain − and ultimately American prosperity

Despite representing only 4% of the world’s population, the United States accounts for over half of science Nobel Prizes awarded since 2000, hosts seven of The Times Higher Education Top 10 science universities, and incubates firms such as Alphabet (Google), Meta and Pfizer that turn federally funded discoveries into billion-dollar…

The Conversation

inkl

Read news from The Economist, FT, and more,
with one subscription

Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook

Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year historical average P/E ratio.

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines.

International Business Times UK

MEPs seek Commission President von der Leyen's resignation with censure motion

MEPs seek Commission President von der Leyen's resignation with censure motion

Supporters of a motion of censure against Commission President Ursula von der Leyen hope it will put enough political pressure on her leadership to force a resignation – mirroring the 1999 downfall of Commission President Jacques Santer.

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Unusually Active Put Options Signal Long Straddle Opportunity After Zoetis Downgrade

Unusually Active Put Options Signal Long Straddle Opportunity After Zoetis Downgrade

Stifel Financial downgraded Zoetis stock on Wednesday, causing the animal health company’s shares to fall 4% on the news. The analyst downgrade created a possible long straddle for options investors. The question is whether it’s the best strategy.

Is Pfizer Stock Underperforming the S&P 500?

Is Pfizer Stock Underperforming the S&P 500?

Pfizer has underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

Can Birth Control Give You Brain Tumors? These 400 Women Say The Pfizer Shot Did

Can Birth Control Give You Brain Tumors? These 400 Women Say The Pfizer Shot Did

Hundreds of women allege Pfizer's contraceptive injection caused tumors, accusing the company of ignoring known dangers and insufficient safety warnings.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

The Guardian - US

A ‘war on children’: as US changes Covid vaccine rules, parents of trial volunteers push back

Frustration and anger mount as Trump administration contemplates new trials and restrictions for Covid vaccines

"Brussels, my love?" Surrender summit or Reset Summit?

An EU–UK summit took place in London this week marking a significant step in post-Brexit relations.

Pfizer's 7.5% Dividend: Income Haven or House of Cards?

Pfizer's high dividend yield warrants scrutiny regarding its sustainability, given changing revenues and pipeline investments.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter

Commission's Pfizergate loss hailed as ‘victory for transparency’

The EU Court ruled against the Commission for failing to justify its refusal to release texts between von der Leyen and Pfizer’s CEO. Critics say the Commission’s actions undermine public trust and accountability, calling for greater transparency in decision-making.

Radio France Internationale

European court delivers blow to EU Commission over Von der Leyen-Pfizer texts

The European Court of Justice has upheld a transparency challenge over undisclosed text messages between EU Commission President Ursula von der Leyen and Pfizer’s CEO during the Covid-19 vaccine negotiations.

How the love story between von der Leyen and Pfizer turned sour

From making her Europe’s vaccine saviour to becoming a skeleton in her closet: All the ebbs and flows in the love story between Ursula von der Leyen and big pharma Pfizer.

The Guardian - UK

Von der Leyen’s texts with Pfizer boss can be shared, says EU’s highest court

European court of justice says no ‘plausible explanation’ given for denying New York Times access to texts from pandemic

EU Commission loses on all counts in Pfizergate legal case

The EU’s top court annulled the Commission’s decision to deny the newspaper New York Times access to messages exchanged between President Ursula von der Leyen and Pfizer CEO Albert Bourla, finding that the EU executive failed to plausibly explain why it does not possess the texts.

The Independent UK

Court rules in favor of the New York Times over texts between an EU chief and a pharma boss

A top European court says the European Commission was wrong to refuse the New York Times access to text messages sent between President Ursula von der Leyen and a pharmaceutical boss during the COVID-19 pandemic

1 … 9 10 11 12

People

191,725 stories

Ursula von der Leyen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The New York Times

The European Union

European Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

377,758 stories

139,834 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play